The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Neurogenetic Testing Market Research Report 2025
Synopsis
Any defect in one or more genes that affect the nervous system can lead to a neurogenetic disorder. Neurogenetic testing is a test for neurogenetic disorders such as dementia, inherited neuropathies, Parkinson's disease, epilepsy, and more.
The global Neurogenetic Testing market was valued at US$ 477 million in 2023 and is anticipated to reach US$ 1028.3 million by 2030, witnessing a CAGR of 11.8% during the forecast period 2024-2030.
Global key players of neurogenetic testing include Quest Diagnostics, Mayo Clinic, GeneDx, Illumina, Labcorp, etc. The top five players hold a share over 28%. In terms of product type, Exome Sequencing is the largest segment, occupied for a share of 44%, and in terms of application, Hospitals has a share about 46 percent.
This report aims to provide a comprehensive presentation of the global market for Neurogenetic Testing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neurogenetic Testing.
Report Scope
The Neurogenetic Testing market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Neurogenetic Testing market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neurogenetic Testing companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Quest Diagnostics
Mayo Clinic
GeneDx
Illumina
Labcorp
Invitae
MedGenome Labs
Connecticut Children’s
CENTOGENE
Victorian Clinical Genetics Services
PacBio
Segment by Type
Exome Sequencing
Whole Genome Sequencing
RNA Sequencing
General DNA Testing
Segment by Application
Hospitals
Specialty Clinics
Research Institutes
Diagnostics Laboratories
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neurogenetic Testing companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Any defect in one or more genes that affect the nervous system can lead to a neurogenetic disorder. Neurogenetic testing is a test for neurogenetic disorders such as dementia, inherited neuropathies, Parkinson's disease, epilepsy, and more.
The global Neurogenetic Testing market was valued at US$ 477 million in 2023 and is anticipated to reach US$ 1028.3 million by 2030, witnessing a CAGR of 11.8% during the forecast period 2024-2030.
Global key players of neurogenetic testing include Quest Diagnostics, Mayo Clinic, GeneDx, Illumina, Labcorp, etc. The top five players hold a share over 28%. In terms of product type, Exome Sequencing is the largest segment, occupied for a share of 44%, and in terms of application, Hospitals has a share about 46 percent.
This report aims to provide a comprehensive presentation of the global market for Neurogenetic Testing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neurogenetic Testing.
Report Scope
The Neurogenetic Testing market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Neurogenetic Testing market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neurogenetic Testing companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Quest Diagnostics
Mayo Clinic
GeneDx
Illumina
Labcorp
Invitae
MedGenome Labs
Connecticut Children’s
CENTOGENE
Victorian Clinical Genetics Services
PacBio
Segment by Type
Exome Sequencing
Whole Genome Sequencing
RNA Sequencing
General DNA Testing
Segment by Application
Hospitals
Specialty Clinics
Research Institutes
Diagnostics Laboratories
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neurogenetic Testing companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neurogenetic Testing Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Exome Sequencing
1.2.3 Whole Genome Sequencing
1.2.4 RNA Sequencing
1.2.5 General DNA Testing
1.3 Market by Application
1.3.1 Global Neurogenetic Testing Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Specialty Clinics
1.3.4 Research Institutes
1.3.5 Diagnostics Laboratories
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Neurogenetic Testing Market Perspective (2019-2030)
2.2 Neurogenetic Testing Growth Trends by Region
2.2.1 Global Neurogenetic Testing Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Neurogenetic Testing Historic Market Size by Region (2019-2024)
2.2.3 Neurogenetic Testing Forecasted Market Size by Region (2025-2030)
2.3 Neurogenetic Testing Market Dynamics
2.3.1 Neurogenetic Testing Industry Trends
2.3.2 Neurogenetic Testing Market Drivers
2.3.3 Neurogenetic Testing Market Challenges
2.3.4 Neurogenetic Testing Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neurogenetic Testing Players by Revenue
3.1.1 Global Top Neurogenetic Testing Players by Revenue (2019-2024)
3.1.2 Global Neurogenetic Testing Revenue Market Share by Players (2019-2024)
3.2 Global Neurogenetic Testing Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Neurogenetic Testing Revenue
3.4 Global Neurogenetic Testing Market Concentration Ratio
3.4.1 Global Neurogenetic Testing Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neurogenetic Testing Revenue in 2023
3.5 Neurogenetic Testing Key Players Head office and Area Served
3.6 Key Players Neurogenetic Testing Product Solution and Service
3.7 Date of Enter into Neurogenetic Testing Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Neurogenetic Testing Breakdown Data by Type
4.1 Global Neurogenetic Testing Historic Market Size by Type (2019-2024)
4.2 Global Neurogenetic Testing Forecasted Market Size by Type (2025-2030)
5 Neurogenetic Testing Breakdown Data by Application
5.1 Global Neurogenetic Testing Historic Market Size by Application (2019-2024)
5.2 Global Neurogenetic Testing Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Neurogenetic Testing Market Size (2019-2030)
6.2 North America Neurogenetic Testing Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Neurogenetic Testing Market Size by Country (2019-2024)
6.4 North America Neurogenetic Testing Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Neurogenetic Testing Market Size (2019-2030)
7.2 Europe Neurogenetic Testing Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Neurogenetic Testing Market Size by Country (2019-2024)
7.4 Europe Neurogenetic Testing Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Neurogenetic Testing Market Size (2019-2030)
8.2 Asia-Pacific Neurogenetic Testing Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Neurogenetic Testing Market Size by Region (2019-2024)
8.4 Asia-Pacific Neurogenetic Testing Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Neurogenetic Testing Market Size (2019-2030)
9.2 Latin America Neurogenetic Testing Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Neurogenetic Testing Market Size by Country (2019-2024)
9.4 Latin America Neurogenetic Testing Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neurogenetic Testing Market Size (2019-2030)
10.2 Middle East & Africa Neurogenetic Testing Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Neurogenetic Testing Market Size by Country (2019-2024)
10.4 Middle East & Africa Neurogenetic Testing Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Quest Diagnostics
11.1.1 Quest Diagnostics Company Detail
11.1.2 Quest Diagnostics Business Overview
11.1.3 Quest Diagnostics Neurogenetic Testing Introduction
11.1.4 Quest Diagnostics Revenue in Neurogenetic Testing Business (2019-2024)
11.1.5 Quest Diagnostics Recent Development
11.2 Mayo Clinic
11.2.1 Mayo Clinic Company Detail
11.2.2 Mayo Clinic Business Overview
11.2.3 Mayo Clinic Neurogenetic Testing Introduction
11.2.4 Mayo Clinic Revenue in Neurogenetic Testing Business (2019-2024)
11.2.5 Mayo Clinic Recent Development
11.3 GeneDx
11.3.1 GeneDx Company Detail
11.3.2 GeneDx Business Overview
11.3.3 GeneDx Neurogenetic Testing Introduction
11.3.4 GeneDx Revenue in Neurogenetic Testing Business (2019-2024)
11.3.5 GeneDx Recent Development
11.4 Illumina
11.4.1 Illumina Company Detail
11.4.2 Illumina Business Overview
11.4.3 Illumina Neurogenetic Testing Introduction
11.4.4 Illumina Revenue in Neurogenetic Testing Business (2019-2024)
11.4.5 Illumina Recent Development
11.5 Labcorp
11.5.1 Labcorp Company Detail
11.5.2 Labcorp Business Overview
11.5.3 Labcorp Neurogenetic Testing Introduction
11.5.4 Labcorp Revenue in Neurogenetic Testing Business (2019-2024)
11.5.5 Labcorp Recent Development
11.6 Invitae
11.6.1 Invitae Company Detail
11.6.2 Invitae Business Overview
11.6.3 Invitae Neurogenetic Testing Introduction
11.6.4 Invitae Revenue in Neurogenetic Testing Business (2019-2024)
11.6.5 Invitae Recent Development
11.7 MedGenome Labs
11.7.1 MedGenome Labs Company Detail
11.7.2 MedGenome Labs Business Overview
11.7.3 MedGenome Labs Neurogenetic Testing Introduction
11.7.4 MedGenome Labs Revenue in Neurogenetic Testing Business (2019-2024)
11.7.5 MedGenome Labs Recent Development
11.8 Connecticut Children’s
11.8.1 Connecticut Children’s Company Detail
11.8.2 Connecticut Children’s Business Overview
11.8.3 Connecticut Children’s Neurogenetic Testing Introduction
11.8.4 Connecticut Children’s Revenue in Neurogenetic Testing Business (2019-2024)
11.8.5 Connecticut Children’s Recent Development
11.9 CENTOGENE
11.9.1 CENTOGENE Company Detail
11.9.2 CENTOGENE Business Overview
11.9.3 CENTOGENE Neurogenetic Testing Introduction
11.9.4 CENTOGENE Revenue in Neurogenetic Testing Business (2019-2024)
11.9.5 CENTOGENE Recent Development
11.10 Victorian Clinical Genetics Services
11.10.1 Victorian Clinical Genetics Services Company Detail
11.10.2 Victorian Clinical Genetics Services Business Overview
11.10.3 Victorian Clinical Genetics Services Neurogenetic Testing Introduction
11.10.4 Victorian Clinical Genetics Services Revenue in Neurogenetic Testing Business (2019-2024)
11.10.5 Victorian Clinical Genetics Services Recent Development
11.11 PacBio
11.11.1 PacBio Company Detail
11.11.2 PacBio Business Overview
11.11.3 PacBio Neurogenetic Testing Introduction
11.11.4 PacBio Revenue in Neurogenetic Testing Business (2019-2024)
11.11.5 PacBio Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest IT & Electronics Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
